ClinicalTrials.gg
Status unknownNCT03368274Updated Apr 11, 2018

To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom

A Phase 4 interventional study of T 614 in IgG4-related Disease, sponsored by Wen Zhang. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-04-11.

Sponsored by Wen Zhang · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Apr 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Immunoglobulin G4-Related Disease with a site in China — 24 open to participants now, 28 under way, 5 of them phase 3. Immunoglobulin G4-Related Disease · China.

Planned enrollment
25th of 37
30 · median 58
Started
2017
the only one that year
Phase 4
3 of 41
none open now
Registered
7th of 41
by date
Lead sponsor
3 of 41
Wen Zhang

Among the 41 studies in Immunoglobulin G4-Related Disease with a site in China, this one is the 25th largest by planned enrollment of the 37 interventional ones that give a count, is the only one that started in 2017, is one of 3 in phase 4, and was the 7th registered.

Immunoglobulin G4-Related Disease

72 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

24 of the 41 studies in Immunoglobulin G4-Related Disease with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Immunoglobulin G4-Related Disease with a site in China, or all of them as a file.
02

Study summary

30 untreated IgG4 related disease (IgG4-RD) patients with mild symptom are enrolled in this study, and will be treated with one dose of diprospan,then take Iguratimod 25mg, Bid orally. Patient's peripheral blood will be collected at baseline, 12 weeks and 24 weeks of follow up. The clinical efficacy will be evaluated by the IgG4-RD responder index, serum immunoglobulin, IgG4 and IgE, cytokines, and peripheral blood T cell and B cell sub-populations will be measured at baseline and follow up.

Read the detailed description

Glucocorticoid is the recognized first-line medication for IgG4-RD, but it has many side effects. In order to avoid long time glucocorticoids intake, patients with mild disease will be treated with Iguratimod combined with one dose of diprospan. 30 untreated IgG4-RD patients with mild symptom will be enrolled in this study, and be treated with one dose of diprospan,then take Iguratimod 25mg, Bid orally. 5 ml of patients' peripheral blood will be collected at baseline, 12 weeks and 24 weeks of follow up. At baseline and each follow-up, the clinical efficacy of treatment will be evaluated by IgG4-RD responder index, serum immunoglobulin, IgG4, immunoglobulin E (IgE), serum cytokines, such as interleukin 1, 6, and tumor necrosis factor, will be measured by ELISA, peripheral blood T cell sub-populations, B cell sub-populations and plasma cells will be measured by flow-cytometry.

03

Conditions studied

  • IgG4-related Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mikulicz disease, with/without nasosinusitis or lymph node swelling.
  • Without internal organs affected,
  • With slow disease progression.

Exclusion criteria

Exclusion Criteria:

  • Vital organs related:including pancreatitis,retroperitoneal fibrosis, sclerosing cholangitis, lung related, kidney affected, IgG4 related castleman's disease and hypophysitis,
  • Combined with other connective disease,
  • With tumors,
  • Pregnancy or to be pregnant,
  • Active infection, including virus, virus, and tuberculosis.
  • Leucocytopenia, impairment of liver and kidney function,
  • Allergy of Iguratimod, or cannot tolerate Iguratimod.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Signal arm study

    Patients with mild symptom IgG4-RD are enrolled and inject one dosage of diprospan ,then take Iguratimod (T614), 25mg, Bid orally for three months. Firstly, we evaluate IgG4-RD responder index of patients at baseline and follow-up time.We collect the laboratory parameters and blood for lymphocytes subpopulations by flowcytometry.

    Drug: T 614

Interventions

  • DrugT 614

    Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.

    Also known as: diprospan

06

What researchers measure

Primary outcomes

  1. The change of IgG4-RD responder index before treatment and after treatment

    Evaluate patients baseline and follow-up IgG4-RD responder index(disease activity)

    Time frame: 24 weeks

Secondary outcomes

  1. Changes of serum immunoglobulins subclass IgG4 levels

    The IgG4 levels are tested routinely.

    Time frame: 24 weeks

  2. Patients serum cytokines

    patients serum of cytokines detection by ELISA.

    Time frame: 24 weeks

  3. Peripheral blood lymphocytes sub-populations

    Peripheral blood T,B sub-populations by flowcytometry

    Time frame: 24 weeks

  4. Side effects

    Side effects, including laboratory tests will be recorded and tested.

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2017 (actual). Primary completion is estimated for Jun 2018, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2017
First posted
Dec 11, 2017
StartActual
Sep 1, 2017
Primary completionEst.
Jun 1, 2018
CompletionEst.
Jun 1, 2018
Last update
Apr 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03368274
Lead sponsor
Wen Zhang
Responsible party
Wen Zhang (professor, Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Dec 11, 2017
Start date
Sep 1, 2017
Primary completion
Jun 1, 2018 (estimated)
Completion
Jun 1, 2018 (estimated)
Last update
Apr 11, 2018

Study contacts

Wen Zhang
Contact
zhangwen91@sina.com
86-10-69158795
Wen Zhang
study chair · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion